Group 1 - The ongoing dispute over the "AestheFill" product involves Aimei Ke's subsidiary REGEN Biotech, which has been restricted from selling the product in mainland China until arbitration is resolved [1][2] - Aimei Ke confirmed that the recent decision is a procedural matter and does not constitute a final arbitration ruling, indicating that REGEN may still sell AestheFill in mainland China [2][3] - The product AestheFill has been out of stock for two months, affecting downstream medical beauty institutions, although Aimei Ke attributes the shortage to distributor sales strategies [2][3] Group 2 - AestheFill has been rebranded as "Zhen Ai Su Fei," but many institutions still refer to it as "Ai Su Fei," leading to confusion in the market [2][3] - There is a significant price discrepancy between the two names, with "Ai Su Fei" priced as low as 8,700 yuan per 200mg unit, while "Zhen Ai Su Fei" is priced around 21,000 yuan for the same quantity [3] - The ability of Aimei Ke to stabilize the sales and pricing of AestheFill remains uncertain and will require further observation [3]

Core Viewpoint - REGENBiotech, a subsidiary of Aimeike, is currently under a temporary arbitration decision that restricts its ability to sell a specific facial filler product in mainland China and recognizes a local distributor as the exclusive seller [2][3]. Group 1: Arbitration Decision - The Shenzhen International Arbitration Court issued a decision that prohibits REGEN from independently selling the "AestheFill" product in mainland China until the arbitration case is resolved [2]. - The decision confirms that Datou Medical is the exclusive distributor of the product in mainland China and mandates REGEN to continue supplying the product to Datou Medical as per their agreement [2]. - REGEN is not allowed to authorize any third party to sell the product in mainland China and must not provide the product to anyone other than Datou Medical for sales requests [2]. Group 2: Legal Response - Aimeike and REGEN are taking the arbitration matter seriously and have engaged a professional legal team to respond to the situation [3]. - REGEN intends to take all necessary legal actions to modify, suspend, or revoke the temporary measures outlined in the arbitration decision [3]. - The decision is a procedural matter and does not affect the final outcome of the case, which will be determined by the arbitration tribunal [3].

Core Viewpoint - The arbitration progress regarding the exclusive agency rights for "AestheFill" between Aimeike and *ST Suwu has led to significant market reactions, with Aimeike's stock declining and *ST Suwu's stock increasing on the same day [1][2]. Group 1: Arbitration Details - The Shenzhen International Arbitration Court ruled that Aimeike's subsidiary, Regen Biotech, cannot sell "AestheFill" in mainland China and must recognize Datou Medical as the exclusive distributor [1][3]. - Datou Medical's request for additional temporary measures, including the revocation of the exclusive authorization for Lizhen (Xiamen) Medical Technology Co., Ltd., was not granted [2][6]. - The emergency arbitrator confirmed that Datou Medical remains the undisputed exclusive distributor of "AestheFill" in mainland China until a final arbitration decision is made [3][5]. Group 2: Financial Impact - *ST Suwu reported a 27.08% year-on-year decline in revenue for the first half of the year, totaling 636 million yuan, with a net loss of approximately 44.42 million yuan, a 281.63% decrease [7]. - Aimeike's revenue for the same period was 1.299 billion yuan, down 21.59% year-on-year, with a net profit of 789 million yuan, reflecting a 29.57% decline [7]. Group 3: Future Implications - The ongoing arbitration will significantly impact both companies' strategies and developments in the medical aesthetics market, with the arbitration court set to form a tribunal for further proceedings [8].

Core Viewpoint - The arbitration progress regarding the exclusive agency rights of "AestheFill" between Aimeike and *ST Suwu has led to significant market reactions, with Aimeike's stock declining and *ST Suwu's stock increasing on the same day [2][8]. Group 1: Arbitration Details - The Shenzhen International Arbitration Court ruled that Aimeike's subsidiary, Regen Biotech, cannot sell "AestheFill" in mainland China until the arbitration decision is made, affirming that Datou Medical is the exclusive distributor [2][4]. - Datou Medical's request for additional temporary measures, including the revocation of the exclusive authorization for Lizhen (Xiamen) Medical Technology Co., Ltd., was not granted [3][7]. - The emergency arbitrator confirmed that Datou Medical retains its status as the undisputed exclusive distributor of AestheFill in mainland China [4][5]. Group 2: Financial Impact - *ST Suwu reported a revenue of 636 million yuan in the first half of the year, a decrease of 27.08%, with a net loss of approximately 44.42 million yuan, down 281.63% [8]. - Aimeike's revenue for the same period was 1.299 billion yuan, a decline of 21.59%, with a net profit of 789 million yuan, down 29.57% [8]. Group 3: Future Implications - The ongoing arbitration will significantly impact both companies' strategies and developments in the medical aesthetics market, with the final outcome still uncertain [9].

Group 1 - The arbitration court ruled that Regen Biotech, Inc. is prohibited from selling AestheFill in China and must acknowledge that 达透医疗 is the exclusive distributor of the product in the region [1][2] - 达透医疗 has filed for arbitration due to Regen's breach of contract, seeking to confirm the validity of the exclusive agency agreement and claiming initial damages of RMB 1.6 billion, with the right to adjust this amount based on case developments [1] - The arbitration court's decision mandates that Regen must continue supplying AestheFill to 达透医疗 until the final arbitration ruling is made [1] Group 2 - *ST苏吴 stated that the company is currently unable to continue selling AestheFill, and the actual impact will depend on whether Regen complies with the arbitration court's decision [2] - The arbitration court will continue to form an arbitration panel to further review the case, indicating that the final outcome remains uncertain [2]

Core Viewpoint - The change in the name of the agent for the medical device registration certificate does not affect the exclusive agency rights of AestheFill in China, which are valid until August 28, 2032 [1] Company Summary - *ST Suwu's subsidiary, Datou Medical Devices (Shenzhen) Co., Ltd., received a change in the name of the agent for the medical device registration certificate for the polylactic acid facial filler AestheFill [1] - The new agent name is now Lizhen (Beijing) Biotechnology Co., Ltd., replacing Datou Medical Devices (Shanghai) Co., Ltd. [1]